CD86 and neoplasm: Collectively, these findings illustrate that recombinant mRNA vaccine triggers a Schwann cell‐like differentiation in melanoma cells via the EGR3 gene and bolster immune infiltration through the CD86 gene, ultimately resulting in effective tumor control.